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A B S T R A C T   
Aberrant production of reactive oxygen species (ROS) leads to tissue damage accumulation, which is associated 
with a myriad of human pathologies. Although several sensors have been developed for ROS quantification, their 
applications for ROS-related human physiologies and pathologies still remain problematic due to the unstable 
nature of ROS. Herein, we developed Trx1-cpYFP-fRMsr (TYfR), a genetically-encoded fluorescent biosensor with 
the remarkable specificity and sensitivity toward fMetRO (free Methionine-R-sulfoxide), allowing for dynamic 
quantification of physiological levels of fMetRO, a novel indicator of ROS and methionine redox status in vitro 
and in vivo. Moreover, using the sensor, we observed a significant fMetRO enrichment in serum from patients 
with acute coronary syndrome, one of the most severe cardiovascular diseases, which becomes more evident 
following percutaneous coronary intervention. Collectively, this study proposes that fMetRO is a novel biomarker 
of tissue damage accumulation in ROS-associated human pathologies, and that TYfR is a promising tool for 
quantifying fMetRO with potentials in versatile applications.   
1. Introduction 
Reactive oxygen species (ROS) serve as signaling molecules for 
numerous biological processes including development, differentiation, 
and apoptosis. Excess amounts of ROS, however, result in oxidative 
stress leading to the accumulation of damaged DNA, protein, and lipids 
(Schieber and Chandel, 2014; Stadtman, 1992). In this context, dysre-
gulated redox homeostasis has been implicated in a myriad of 
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pathophysiological and physiological conditions, including cancer, 
neurodegenerative, cardiovascular diseases, and aging (Choi et al., 
2019; Liou and Storz, 2010; Zhou et al., 2018). 
Substantial efforts have been made to not only understand the 
biochemical mechanisms underlying ROS implication in the patholog-
ical and physiological conditions, but also to develop biosensors that can 
measure ROS levels. For example, H2O2 levels have been directly 
monitored in vivo and in vitro using a H2O2 sensor, including HyPer, a 
genetically-engineered fluorescence protein including circularly 
permuted yellow fluorescent protein (cpYFP) (Belousov et al., 2006), 
Orp1 sensor using the bacterial H2O2 regulators (Levine et al., 1996; 
Stadtman et al., 2005), and Prx-RoGFP, a recently developed 
peroxiredoxin-based redox-sensitive GFP sensor displaying a higher 
sensitivity compared to the aforementioned sensors, allowing for 
measuring the metabolic H2O2 baseline levels in vivo. YFP and GFP, with 
oxidation on their cysteine residues, have also been exploited to monitor 
changes in ROS levels in vivo and in vitro (Hanson et al., 2004; Oster-
gaard et al., 2001). However, the applications of these sensors for 
monitoring ROS in various physiological and pathological settings still 
remain challenging due to the unstable nature of ROS (Niethammer 
et al., 2009). 
Methionine oxidation is a physiological process by which ROS 
oxidize free methionine (fMet) or protein-based Met (pMet), resulting in 
the production of methionine sulfoxide (MetO) —diastereomers of 
MetO, including methionine-R-sulfoxide (MetRO) and methionine-S- 
sulfoxide (MetSO). Interestingly, such MetO species have recently 
emerged as a relevant ROS indicator due to its higher stability than the 
other previously known indicators such as H2O2 or oxidized cysteine 
(Lee and Gladyshev, 2011). 
Such MetO has been known to be dynamically regulated by MsrA and 
MsrB, reducing enzymes only expressed in multicellular system. Mech-
anistically, MsrA and MsrB reduce MetO to methionine, resulting in the 
intramolecular disulfide bond formation between cysteine 35 and 37 
within the catalytic sites of the reductases. Such oxidized reductases are 
reversed by thioredoxin (Trx) system, through which the enzyme ac-
tivities of the reductases are restored. One of the unique properties of the 
MetO reductases in multicellular system is their differential substrate 
reactivities (Tarrago et al., 2012) (Tarrago and Gladyshev, 2012). For 
example, MsrA efficiently reduces both free methionine-S-sulfoxide 
(fMetSO) and protein-based methionine-S-sulfoxide (pMetSO), 
whereas MsrB displays a higher sensitivity toward protein-based 
methionine-R-sulfoxide (pMetRO), but is essentially inactive with fMe-
tRO (Lee and Gladyshev, 2011), leading to an accumulation of fMetRO. 
Therefore, such fMetRO accumulation, not the other MetO species, led 
us to hypothesize that fMetRO may serve as a biological marker of not 
only ROS per se, but also tissue damage accumulation following oxida-
tive stress in ROS-associated human pathophysiologies. This diagnostic 
potential, together with the physiological relevance of methionine redox 
status in numerous cellular processes including sulfur metabolism, 
signaling pathways and protein synthesis (Klein Geltink and Pearce, 
2019), sparked the scientific interest in developing a biosensor for 
detecting the physiological level of fMetRO. 
Taking advantage of the chemical and biological properties of MetO, 
genetically-engineered fluorescence-based MetO sensors have recently 
been developed to quantitatively measure MetO in vivo and in vitro 
(Tarrago et al., 2015). These sensors have been created by combining 
cpYFP with MsrA and MsrB from Saccharomyces cerevisiae. However, the 
various applications of these sensors in monitoring physiological and 
pathological perturbation of fMetRO have been challenging as they are 
not substantially sensitive to detect the physiological range of free 
MetRO concentration (Lee et al., 2008; Tarrago et al., 2015). Such 
limitations led us to design a new strategy for fMetRO quantification in 
complex biological samples with a high specificity and sensitivity. To 
achieve this, we developed Trx1-cpYFP-fRMsr (TYfR), a novel fluores-
cent biosensor using free methionine-R-sulfoxide reductase (fRMsr), a 
gene from E.coli, which displays a remarkable sensitivity and specificity 
toward fMetRO, but not fMetSO (Lin et al., 2007a). 
Thorough biochemical assessment of TYfR sensor revealed that the 
TYfR displays a remarkable specificity and sensitivity, allowing for 
steady states and real-time measurement of physiological concentrations 
of fMetRO from cells to whole-body levels. More importantly, using the 
TYfR, we found a significant increase in fMetRO levels in human serum 
biopsies from patients with acute coronary syndrome (ACS), one of the 
most severe ROS-related human pathologies, which becomes more 
evident following percutaneous coronary intervention (PCI). Such ob-
servations suggest that our novel platform has the potential to serve as a 
diagnostically relevant tool for dynamic monitoring of ROS and methi-
onine redox status which represents tissue damage accumulation in 
ROS-associated human pathologies. 
2. Results 
2.1. Development of the free methionine-R-sulfoxide-detecting biosensor 
To develop a sensor for detecting a physiological level of fMetRO, 
fRMsr was cloned into an expression vector with mutant Thioredoxin 1 
(Trx1), in which the resolving cysteine was replaced with serine, 
Cys35Ser (Fig. 1). Of note, unlike MsrB in multicellular system, fRMsr 
efficiently and specifically reduces fMetRO, but not fMetSO, through the 
unique coordination between two resolving cysteine residues (Cys84 
and Cys94) located in the catalytic sites of the fRMsr and, Trx system 
(Etienne et al., 2003; Le et al., 2009; Lin et al., 2007a). Then, several 
circular permutated fluorescent protein genes, cpBFP, cpYFP, and cpRFP, 
were inserted between fRMsr and Trx1. Given the natural transient di-
sulfide bond between fRMsr and Trx1, we speculated that fMetRO 
treatment will lead to this intramolecular structural change also when 
the proteins are fused, thereby changing the fluorescence spectra of 
fluorescent proteins that links these oxidoreductases. Interestingly, the 
fusion protein with cpYFP, displayed a specific change in fluorescence 
spectra upon treatment with 10 mM fMetRO (Fig. 1A and B), whereas 
those made with cpBFP or cpRFP were not reactive (Figure S1A-F). We 
named the sensor created with the cpYFP, ‘TYfR’ (Fig. 1A and B). For the 
spectrophotometric characterization of this sensor, we produced the 
recombinant protein and reduced it with glutathione (GSH). The spec-
trophotometric data of reduced TYfR revealed that it displayed two 
peaks for absorbance and excitation with maxima at 430 nm and 500 nm 
and one peak for emission at 535 nm (Fig. 1C and D). fMetRO treatment 
altered the excitation and emission spectra of TYfR; the fluorescence 
intensity of the emission peak increased at 535 nm, while that of the 
excitation peak increased at 500 nm, but not at 430 nm, allowing this 
sensor to be used to detect fMetRO by measuring the ratio of fluores-
cence intensities (RFI) at the two excitation peaks (500 nm/430 nm, 535 
nm for emission) (Figure S2). 
2.2. Characterization of the TYfR biosensor 
The specificity and sensitivity of the TYfR biosensor were also 
determined with various substrates. We first found that the RFI of TYfR 
did not change in the presence of hydrogen peroxide (H2O2), suggesting 
that TYfR specifically monitors fMetO, but not oxidative stress per se 
(Fig. 2A, Figure S2A). This notion is further supported by data in Fig. 2B, 
wherein NaOCl, a strong oxidizing reagent, only changes the RFI of TYfR 
following incubation with Met for MetO production. We also measured 
the RFI of TYfR in the presence of a physiological range of fMetRO (5, 
10, or 20 μM)12 or equivalent concentration of fMetSO. The increase in 
RFI of TYfR was observed at all the tested concentrations of fMetRO, but 
not at any concentration of fMetSO, indicating that TYfR displays high 
substrate specificity and sensitivity (Fig. 2C). Moreover, linear regres-
sion analysis showed that the RFI of TYfR was directly proportional to 
the fMetRO level within the range of fMetRO concentrations tested in 
Fig. 2B, as well as below the nanomolar concentration (Limit of detec-
tion (LOD): 250–500 nM; R2 = 0.9882, p < 0.0001) (Fig. 2D and E), 
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suggesting that the TYfR sensor can quantitatively measure physiolog-
ical concentrations of fMetRO. Of note, MetROx, a pMetRO sensor (Lee 
et al., 2008), failed to show the linear relationship between RFI and 
fMetRO concentration in the physiological range (LOD was not 
measurable in the range tested), although it could still detect the range 
of pMetRO (Fig. 2F and Figure S2B), indicating that MetROx might not 
be a relevant biosensor to measure fMetRO level in vivo. The observa-
tions, taken together with fRMsr displaying a high specificity and 
sensitivity toward fMetRO, led us to propose that TYfR is the first 
developed sensor for quantification of in vivo concentrations of fMetRO. 
We then determined the physiochemical properties of TYfR. We first 
examined the effect of pH on TYfR activity and showed that the 
maximum dynamic range of the sensor was at a pH of 7.5, substantiating 
the experiments performed at pH of 7.5 throughout our study, albeit 
TYfR displayed a higher RFI at pH 8.5 and 9.0 than at any pH conditions 
tested (Figure S2C-D). We also observed that treatment with dithio-
threitol (DTT) (5, 25 or 50 mM) or GSH (3.2 mM) (Figure S2E-F) 
diminished the RFI of TYfR, which led us to use GSH to generate the 
reduced form of TYfR. 
2.3. In vivo testing of the TYfR biosensor 
Nanomolar scale sensitivity (250–500 nM) and high specificity of the 
TYfR sensor led us to examine whether TYfR can detect fMetRO in vivo. 
To achieve this, we transfected a mammalian expression vector encod-
ing TYfR into HEK293FT cells, followed by treatment with 4 mM GSH to 
maintain the transfected TYfR in the same redox state. Single-cell 
confocal microscopy coupled with time series analysis was employed 
to measure dynamic fluorescence changes upon treatment with various 
substrates. We found that the RFI of TYfR increased upon treatment with 
10 mM free methionine-R/S-sulfoxide (fMetO), while GSH treatment led 
to a decrease in RFI (Fig. 3A and C). Notably, 10 mM H2O2 treatment 
resulted in an increase in the RFI of TYfR (Fig. 3B and D). This obser-
vation, together with the results of Fig. 2 A-C, in which TYfR only 
responded to fMetO produced by oxidative stress, but not to oxidative 
stress per se, suggested that the TYfR sensor can specifically monitor 
changes in the cellular levels of fMetRO produced by oxidative stress. 
Differential oxidative stress status observed across various cellular 
organelles (Giorgio et al., 2007; Yoboue et al., 2018) led us to hypoth-
esize that the level of fMetRO may also be different from one organelle to 
Fig. 1. Development and determination of the spectral characteristics of the TYfR sensor 
(A and B) Schematic diagrams of TYfR structure and its potential mechanism of action. cpYFP was fused in frame with fRMsr and Trx1. Trx1 is a mutant in which the 
resolving cysteine 35 has been mutated to serine. fRMsr possesses two resolving cysteine residues (Cysteine 66 and 76 equivalent to cysteine 335 and 345 in Trx1/ 
cpYFP/fRMsr plasmid), which may be responsible for fMetRO reduction 
(C and D) Excitation and emission spectra of reduced and oxidized TYfR. The sensor was oxidized using 10 mM fMetO or reduced using 3.2 mM GSH, followed by 
measurement of the fluorescence at the indicated wavelengths. Data have been presented as mean ± SD from three replicate measurements. 
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another. To test this possibility, we cloned vectors encoding TYfR fused 
with specific peptide sequences that could target TYfR into various 
cellular compartments including cytosol, nucleus, endoplasmic reticu-
lum (ER), and mitochondrial matrix. As shown in Fig. 3E–F and 
Figure S3A-D, surprisingly, TYfR displays higher RFIs in the ER and 
mitochondria, as compared to those in the nucleus and cytosol, sug-
gesting that the fMetRO level may be differentially regulated in these 
organelles. Taken together, we propose that our TYfR sensor can be used 
to quantitatively measure the level of fMetRO at subcellular levels. 
2.4. Detection of endogenous free methionine-R-sulfoxide in serum and 
lysates 
We developed a novel platform through which fMetRO level can be 
Fig. 2. Specificity and sensitivity of TYfR sensor towards fMetRO 
(A and C) Kinetics of reactivity of TYfR towards fMet, fMetO, and various concentrations of H2O2 (A), fMetRO and fMetSO (5, 10, and 20 μM) (C). Fluorescence 
variations in F500 nm/F430 nm ratios for 5 min were normalized to the value at t = 0 (R0). Fluorescence excitation intensity ratios F500 nm/F430 nm were measured from 
spectra recorded at an emission wavelength of 535 nm 
(B) Response of TYfR towards Met oxidized using NaOCl. Values of fluorescence intensity at 20 min were normalized to the value at t = 0 (R0) 
(D) Measurement of fluorescence intensities of TYfR at various concentrations of fMetRO and fMetSO. TYfR was incubated with the indicated concentrations of 
fMetRO or fMetSO. Fluorescence intensities were normalized to fluorescence values of the most oxidized and reduced forms of TYfR within each experiment 
(E) Standard curve of fluorescence intensity of TYfR at the fMetRO concentrations tested in (D). LOD = 250–500 nM, R2 = 0.9882 and p < 0.0001 
(F) Measurement of fluorescence intensity of MetROx at the concentrations of fMetRO and fMetSO tested in (D). MetROx was incubated with the indicated con-
centrations of fMetRO or fMetSO. Fluorescence intensities were normalized to the fluorescence values of the most oxidized and reduced forms of MetROx within each 
experiment 
Data for all experiments are presented as mean ± SD of three replicates 
Abbreviations; Met, methionine; fMetRO, free methionine-R-sulfoxide; fMetSO, free methionine-S-sulfoxide; NaOCl, sodium hypochlorite; H2O2, hydrogen peroxide, 
LOD: Limit of detection 
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Fig. 3. Measurement of subcellular levels of fMetRO in HEK293 cells treated with oxidizing reagents 
(A and C) Time series of raw fluorescent and pseudo-colored images of TYfR in HEK293FT cells before and after sequential addition of 10 mM fMetO and 4 mM GSH 
(A). The arrows indicate the time point at which the substrates were added. Variation in excitation fluorescence intensity ratios (F488/F405) of TYfR in a time series 
analysis (C). The ratio is calculated by dividing the background-subtracted fluorescence at 488 nm to the fluorescence at 405 nm. Data have been presented as mean 
± SD (n = 4–6) 
(B and D) Time series of raw fluorescent and pseudo-colored images of fMetRO sensor in HEK293FT cells treated sequentially with 10 mM H2O2 and 3.2 mM GSH 
(B). The arrows indicate the time point at which the substrates were added. Variation in excitation fluorescence intensity ratios (F488/F405) of TYfR was measured 
using time series analysis (D). The intensity ratio was calculated by dividing the background-subtracted fluorescence at 488 nm by the fluorescence at 405 nm. Data 
have been presented as mean ± SD (n = 4–6) 
(E and F) Representative images of fluorescence signal from TYfR expressed in different cellular compartments obtained using confocal microscopy (E). Scale bar, 20 
μm. The fluorescence intensity ratio (F488/F405) of TYfR was measured in the different compartments (F). Fluorescence was activated at 488 nm and 405 nm. 
Emission range was >505 nm **p < 0.01 (Bonferroni test). Abbreviations: ER, endoplasmic reticulum; GSH, glutathione. 
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measured in various types of biological samples (Fig. 4A). Biological 
samples (e.g., cell lysates and serum from mice) were incubated with the 
fully reduced TYfR sensor, following their deproteinization to avoid 
background signal due to macromolecules in the samples. Upon using 
this platform, we observed a significant increase in RFI, which is pro-
portional to the level of oxidants treated in HEK293FT lysates, sug-
gesting the tool suited for in vivo quantification of fMetRO (Fig. 4B and 
C). 
We further investigated whether such a platform is applicable to 
tissue samples, such as serum from mouse models of ROS production. To 
this end, we tested the serum from mice challenged with destabilization 
of medical meniscus (DMM) surgery, which has been implicated in 
systemic ROS production (Lee et al., 2008; Lepetsos and Papavassiliou, 
2016). Notably, DMM surgery led to a significant increase in the serum 
level of fMetRO, as evidenced by the higher RFI of TYfR incubated with 
the serum from mice that underwent DMM surgery when compared to 
the serum from mice that underwent sham surgery (Fig. 4D). More 
surprisingly, we observed that TYfR sensor becomes fluorescently acti-
vated in vivo following injection of the TYfR sensor and As2O3, a 
chemical that induces oxidative stress (in the form of H2O2) leading to 
systemic ROS production and tissue damage (Hu et al., 2020), suggest-
ing that TYfR can also be employed for real-time measurement of in vivo 
fMetRO (Fig. 4E and F). In addition, TYfR also detected the accumula-
tion of fMetRO in the serum extracted from As2O3-treated mice over a 
time period of 12 h (Fig. 4G). Such observations suggest that fMetRO 
may be a relevant indicator of the dynamic methionine redox status 
which represents tissue damage accumulation following oxidative 
stress. These findings, taken together with our powerful platform, 
affirmed the potential use of TYfR for measuring damage accumulation 
following oxidative stress in the context of ROS-related human 
pathologies. 
2.5. Clinical implication of TYfR use to measure oxidative stress during 
myocardial ischemia-reperfusion injury 
A massive burst of ROS is a pathophysiological consequence of 
restored blood flow following PCI for treating ACS including myocardial 
infarction and unstable angina (Granger and Kvietys, 2015) (Fig. 5A), 
leading to severe tissue damage near the surgical regions. 
We tested whether TYfR can be employed as a relevant tool for 
measuring the accumulated tissue damage following increased oxidative 
stress following PCI. For this, the levels of fMetRO were measured in 
human serum biopsies from 1) control subjects having chest pain, but 
with normal coronary arteries (control, n = 8), and 2) ACS patients (n =
9) before and after PCI (Fig. 5A and B). First, we observed whether there 
was significant increase in fMetRO levels in serum from ACS patients as 
compared to those in the serum from control subjects (Fig. 5B), con-
firming the well-established correlation between oxidative stress and 
ACS incidence. More importantly, across all the patients tested, fMetRO 
levels were significantly higher in the serum collected a day after PCI (p 
= 0.0055) (Fig. 5C); this is consistent with a previous report showing 
that the serum ROS level in a canine model of PCI remained high for a 
day after PCI (Bolli et al., 1989). Such an observation in the human 
biopsies from ACS patients undergoing PCI highlighted the potential use 
of fMetRO as a novel biomarker for accumulated tissue damage 
following oxidative stress in ROS-associated human pathophysiology. 
3. Discussion 
fMetRO has recently been proposed as a biological indicator of ROS, 
owing to its better stability than the other known ROS indicators 
including such as H2O2, cysteine, and sulfenic acid (Claiborne et al., 
1993). For example, a significant accumulation of fMetRO levels has 
been observed in the serum from mice challenged to various forms of 
oxidative stress, in aged mice and mice fed on a selenium-deficient diet 
(Lee et al., 2008). However, physiological and pathological relevance of 
fMetRO in various ROS-related physiologies and pathologies have yet to 
be explored, due to the lack of a sensor for the detection of fMetRO 
concentration in the physiological range. For example, 1) high perfor-
mance liquid chromatography (HPLC) method, which has been previ-
ously used to measure fMetRO (Lee et al., 2008), was able to detect the 
range of 5 μM–500 μM concentration of fMetRO (Figure S4A) although it 
failed to detect either nM concentration of fMetRO in vitro or more 
complex biological samples such as fMetRO in serum biopsies 
(Figure S4B). 2) Gas chromatography-mass spectrometry (GC/MS-MS) 
has been shown to detect fMetO with a high sensitivity following a 
specific derivatization method (Sochaski et al., 2001) (Figure S4C–F). 
However, the caveat of the method is that it cannot distinguish fMetRO 
from fMetSO, not allowing for a specific detection of fMetRO, a previ-
ously unrecognized marker of tissue damage accumulation following 
ROS production. Such observations, taken together with the character-
ization of fRMsr, an efficient fMetRO reductase found in prokaryotes and 
unicellular eukaryotes (Lin et al., 2007b), led to the development of 
TYfR, the first version of fMetRO sensor with a clinical potential. 
To develop the TYfR, we introduced fRMsr and cpYFP genes into a 
vector with mutant Trx1 in which the resolving cysteine 35 was 
substituted with serine. We found that TYfR is a ratiometric fluorescent 
sensor with a high specificity toward fMetRO, but not in response to 
either fMetSO or strong oxidizing reagents, allowing for the specific 
quantification of fMetRO by measuring RFI at the two excitation peaks 
(500 nm/430 nm). TYfR also has unique physiochemical properties, 
which led us to conduct the experiments in a specific condition wherein 
a fully reduced sensor was used to measure fMetRO level of various 
samples at pH 7.5. 
Notably, the fMetRO sensitivity of the sensor (250 nM–500 nM) was 
much higher than that of MetROx, a previously designed pMetRO sensor 
(Tarrago et al., 2012); such a high sensitivity of the TYfR supports the 
detection of fMetRO in the physiological range of concentrations. When 
transfected into 293FT cells, TYfR sensor could also monitor fMetRO in 
vivo. We also observed that TYfR displayed specific and differential RFIs 
according to its subcellular localization, suggesting that subcellular level 
of fMetRO may be differentially regulated; ER and mitochondria may be 
more fMetRO-enriched as compared to cytosol and nucleus. Indeed, this 
notion is concordant with recent studies in which mitochondria and ER 
were proposed as organelles with the most prevalent ROS production 
(Malinouski et al., 2011; Yoboue et al., 2018). However, we do not rule 
out the possibility that such differences attribute to the unique subcel-
lular environment (e.g. subcellular GSH level and pH), which should be 
further addressed. This observation, taken together with 1) quantifica-
tion of ROS in intact cells or cell lysates treated with oxidative stressor, 
2) steady state and real-time measurement of fMetRO in two mouse 
models of systemic ROS production, suggest that TYfR and its substrate 
can also be employed as a molecular biology platform for dynamic 
monitoring of physiological and pathological production of (sub)cellular 
ROS level with a high sensitivity and reproducibility, which would be 
greatly useful for studying ROS-related signaling pathway and molecu-
lar dynamics in vitro and in vivo. 
ROS biology has long been implicated in the pathology of the car-
diovascular system (Panth et al., 2016). For example, aberrant local 
production of ROS results in protein and lipid oxidation, leading to 
subsequent endothelial dysfunction and inflammation, which further 
increases ROS levels at the site of pathology (Vichova and Motovska, 
2013). Such a positive feedforward event has been shown to increase the 
incidence of ACS, one of the most severe cardiovascular diseases. 
Paradoxically, it has also been shown that clinical strategies, including 
PCI and fibrinolytic therapy for restoration of blood flow in ACS pa-
tients, also transiently provoke the positive loop, by causing a drastic 
spike in ROS production at the reperfusion site, which could lead to 
severe tissue damage in cardiomyocytes and subsequent necrotic cell 
death. This pathological phenomenon is referred to as ischemia reper-
fusion injury, which should be carefully monitored after therapy (Zhou 
et al., 2018). In this context, characterizing biomarkers of tissue damage 
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Fig. 4. Application of TYfR for detection of fMetRO in cell lysates and serum from HEK293FT cells and mice challenged with oxidative stress, respectively 
(A) Experimental procedure for TYfR application in fMetRO measurement in cell lysates or mouse serum 
(B) TYfR response to fMetRO in HEK293FT cell lysates treated with H2O2. The lysates were first deproteinized using trichloroacetic acid. The fluorescence intensity 
ratio (F500/F430) was normalized to total protein concentration. Data are presented as mean ± SD from six replicates 
(C) TYfR response to fMetRO in HEK293FT cell lysates treated with NaOCl. The lysates were deproteinized using trichloroacetic acid prior to the reaction. The 
fluorescence intensity ratio (F500/F430) was normalized to total protein concentration. Data are presented as mean ± SD from six replicates 
(D) Response of TYfR to serum fMetRO of mice that underwent sham or DMM surgery. Fluorescence intensities were normalized to the fluorescence values of the 
most oxidized and reduced forms of TYfR within each experiment. Data are presented as mean ± SD from three biological replicates 
(E and F) In vivo multispectral imaging of immune-compromised mice subjected to intravenous injection of TYfR and intraperitoneal injection of As2O3 for indicated 
time periods. Excitation and longpass emission filters with wavelengths of 435–480 nm and 490 nm, respectively, were used 
(G) Response of TYfR to serum fMetRO in As2O3-treated mice. Fluorescence intensities were normalized to the fluorescence values of the most oxidized and reduced 
forms of TYfR within each experiment. Data are presented as mean ± SD from three biological replicates.Abbreviations: AS2O3, arsenic trioxide; DMM, destabili-
zation of the medial meniscus. 
D.W. Choi et al.                                                                                                                                                                                                                                 
Biosensors and Bioelectronics 178 (2021) 113031
8
in patients undergoing PCI, followed by the development of a platform 
with corresponding sensors, are of great importance. Moreover, such a 
platform can also be employed for testing the efficiency of various an-
tioxidants in ameliorating increased ROS levels in patients undergoing 
PCI, as well as in patients with other ROS-related diseases. 
Our newly developed sensor has the diagnostic potential for 
measuring the accumulated tissue damage induced by oxidative stress in 
human pathologies relevant to ROS. This is evident from the observa-
tions in which TYfR detects 1) significant enrichment of fMetRO in 
serum biopsies from ACS patients versus that in control subjects and 2) 
the dramatic rise in serum levels of fMetRO in ACS patients undergoing 
PCI. 
Finally, we provide the first clinical evidence that MetRO is a 
promising biomarker for accrued damage induced by oxidative stress in 
ROS-related human pathologies. This may not only be the consequence 
of the aberrant ROS production, but also contributes to the pathogenesis 
of ROS-related diseases, given that intracellular pool of free methionine 
and its intermediates has been implicated in regulating several meta-
bolic pathways including protein translation, transsulfuration and one 
carbon pathways (Roy et al., 2020; Shiraki et al., 2014), all of which are 
tightly associated with cellular responses to aberrant ROS production. In 
this regard, TYfR sensor may also be a promising tool for expanding our 
knowledges on how methionine-related pathways and the relevant 
physiological processes (e.g. glutathione metabolism and epigenetic 
regulation) can be regulated in the context of ROS-related human 
diseases. 
Therefore, understanding the mechanism of fMetRO regulation and 
its pathophysiological relevance in the context of various ROS-related 
diseases will significantly expand the clinical potential of the TYfR 
sensor. 
4. Conclusions 
Our TYfR sensor is the first genetically-encoded fluorescent 
biosensor displaying a remarkable sensitivity and specificity toward 
fMetRO (free Methionine-R-sulfoxide), allowing for steady state and 
real-time quantification of ROS and methionine redox status from cells 
to whole-body level. We believe that the TYfR sensor possesses a greatly 
relevant potential for studying ROS-related human physiologies and 
pathologies. 
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